Big Pharma Can't Merge Its Way Out Of An Innovation Problem
By Jim Healy, M.D., Ph.D., Managing Partner, Sofinnova Investments
Over the weekend, the Financial Times reported that AstraZeneca and Bristol Myers Squibb were exploring what would have been the largest pharmaceutical merger in history. The news sent AstraZeneca's shares tumbling nearly 9% - its biggest one-day decline since 2020 - as investors questioned the strategic rationale for combining one of the industry's strongest-performing companies with a peer facing slowing growth.
Just days later, Reuters poured cold water on the speculation. Citing senior sources close to the matter, Reuters reported there were "no discussions" between the companies, "there never was a deal to be done," and no active negotiations underway. According to Reuters, given the size of such a transaction, U.K. market rules would likely have required disclosure had formal negotiations been taking place.
Whether the merger was ever real or simply market speculation is almost beside the point. The headlines reignited an important conversation about the future of the pharmaceutical industry, and whether ever-larger mergers are the answer to slowing growth, looming patent cliffs, and declining research productivity.
They are not.
The pharmaceutical industry's biggest challenge today isn't scale — it's innovation.
For decades, mega-mergers have followed a familiar playbook. When companies face slowing revenue growth or looming patent expirations, they pursue transformational acquisitions promising billions of dollars in cost synergies. Investors hear about expanded pipelines, diversified revenue, and stronger global reach.
But history suggests these deals rarely solve the underlying innovation challenge.
The pharmaceutical industry has been here before.
Pfizer's $68 billion acquisition of Wyeth and Merck's $41 billion acquisition of Schering-Plough in 2009 were both driven largely by patent cliffs. Those transactions generated significant cost savings but also led to extensive restructuring, research site closures, and tens of thousands of layoffs.
A decade later, Bristol Myers Squibb acquired Celgene for $74 billion, while Takeda transformed itself through its acquisition of Shire. These deals strengthened portfolios and created larger organizations, but they also required years of integration, organizational restructuring, portfolio rationalization, and management focus before leadership could fully return its attention to innovation.
To be fair, many of these transactions created shareholder value but they did not necessarily lead to better patient outcomes. But cost synergies are not the same as scientific breakthroughs, and that's the distinction that matters.
The reality is that many large pharmaceutical companies are increasingly relying on external innovation to replenish their pipelines.
We've had a front-row seat to that trend.
Both Bristol Myers Squibb and AstraZeneca have acquired Sofinnova portfolio companies to strengthen their innovation engines. Bristol Myers Squibb acquired Karuna Therapeutics and RayzeBio. AstraZeneca acquired Cincor Therapeutics. Those emerging biotechnology companies developed transformative medicines that ultimately became strategic priorities for two of the world's largest pharmaceutical companies.
Those acquisitions were successes - for patients, entrepreneurs, investors, and the acquiring companies. But they also illustrate a broader reality. The next generation of breakthrough medicines increasingly originates in venture-backed biotechnology companies, not within the walls of the largest pharmaceutical organizations.
Large pharmaceutical companies remain indispensable. They excel at conducting global clinical trials, navigating complex regulatory pathways, manufacturing medicines at scale, and bringing therapies to patients worldwide. Biotech, however, is where much of the earliest scientific innovation begins.
That's why another pharmaceutical mega-merger - even if it never materializes - raises an important question.
What happens when two of the industry's largest business development organizations become consumed with integrating themselves?
Leadership attention inevitably shifts inward. Business development teams focus on eliminating overlap, rationalizing portfolios, integrating cultures, and achieving promised synergies. Capital that might otherwise support licensing deals, strategic partnerships, expanding clinical programs or acquisitions of innovative biotech companies is redirected toward financing the merger and delivering cost savings.
For the biotechnology ecosystem, that's a meaningful consequence.
Fewer active pharmaceutical buyers mean fewer partnership opportunities. Acquisition activity slows. Licensing decisions take longer. Entrepreneurs have fewer paths to bring breakthrough science to patients.
At precisely the moment when the industry needs greater investment in external innovation, its largest players risk becoming distracted by internal integration.
That's why a merger between AstraZeneca and Bristol Myers Squibb would have felt less like a bold strategic leap and more like a sideways move. It doesn't solve the industry's fundamental problem. It simply creates a bigger company with the same challenges.
Rather than asking whether pharmaceutical companies should become larger, perhaps we should ask whether they can become better partners to innovation.
The companies that will define the next decade won't necessarily be those with the biggest market capitalizations. They will be the ones that continue identifying transformative science wherever it emerges, partnering with entrepreneurs, licensing breakthrough technologies, and acquiring innovative companies before they become obvious successes.
Innovation cannot be merged into existence. It involves creativity and must be discovered, funded, nurtured, and developed.
About The Author:
Jim Healy, M.D., Ph.D. is Managing Director at Sofinnova, where he has invested in 32 companies over 20 years at the company, leading to 13 products approved by the FDA or EMA. Jim is a board member at ArriVent, BioAge, Rapport, and Seaport, and most recently served as board member for Karuna (acquired by BMS for $14B), and was Chairman of CinCor (acquired by AstraZeneca for $1.8B). Prior to Sofinnova, Jim worked at Bayer (Miles) and Sanderling. He has lectured on entrepreneurship at Stanford University and served on the boards of the Executive Committee at UC Berkeley, the National Venture Capital Association (NVCA) and the Biotechnology Innovation Organization (BIO).